JFB Construction Holdings Announces Commencement of a $21 Million Construction Contract, Largest in its History


Construction on 79-Unit Development, The Preserve at Port Salerno, Expected to Commence by May 1, 2025

Lantana, FL, April 16, 2025 (GLOBE NEWSWIRE) — JFB Construction Holdings (Nasdaq: JFB), a construction company focused on commercial, retail, and residential property development, announces that it is commencing the largest single multi-family development construction contract in company history, valued at $21 million. The Company will act as the general contractor for The Preserve at Port Salerno, a 79-unit townhome development with clubhouse and pool amenities in Port Salerno, Florida.

“We believe that the increased proliferation of larger multi-family residential developments such as condominiums and townhouses will be instrumental in JFB’s growth,” said CEO Joseph F. Basile, III. “The Preserve project agreement, our largest single contract ever in which we will serve as the general contractor, is a 79-unit townhome development with an additional community clubhouse and amenities with a designated preserve area. We believe projects such as this one will be key to our future success, providing increased opportunity to manage larger construction projects and establish our continued leadership among our regional competitors in managing jobs at this scale.”

The Preserve at Port Salerno is a new luxury townhome project of upscale two-story rental townhomes ranging from 1600 to 1700 square feet, located within quiet Port Salerno / Stuart, Florida. The community offers luxurious yet earth-friendly amenities and is located within minutes of the Intracoastal Highway, Atlantic Ocean, and Stuart Airport, providing effortless access to the South Florida urban-coastal lifestyle.

About JFB Construction Holdings

JFB Construction Holdings (“JFB”) offers generations of combined experience in residential and commercial construction and development. Having the experience of building Multifamily communities, Shopping Centers, National Franchises, exclusive estate & equestrian homes, and over 2 million square feet of commercial and retail. JFB provides hands-on, professional expertise, which has led to the quality and production we are known for.

JFB’s reputation has been built on its clients’ trust and the value it brings to each project.

JFB is proud that most of its projects are obtained through 100% referrals and repeat customers, and that to-date it has provided general contracting and construction management services in 36 U.S. states.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements”. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. Actual results could vary materially from the expectations and projections of JFB Construction. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including statements regarding the use of proceeds from the sale of our shares in the Offering; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in JFB Construction’s prospectus filed with the SEC. We do not undertake to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

JFB Construction Holdings Contact:

Joseph F. Basile, III
561-582-9840.
[email protected]

Investor Relations Contact:

CORE IR
Mike Mason
516 222 2560
[email protected]



Talkspace to Report First Quarter 2025 Results and Host Conference Call

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that it will release its first quarter 2025 results on Tuesday, May 6, 2025, before market open and host a conference call to review the results at 8:30am ET.

Conference Call Details
The conference call will be available via audio webcast at https://investors.talkspace.com/ and can also be accessed by dialing (888) 596-4144 for U.S. participants, or +1 (646) 968-2525 for international participants, and referencing participant code 1021845. A replay will be available shortly after the call’s completion and remain available for approximately 90 days.

About Talkspace
Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare provider committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall health and should be available to everyone.

Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services, including therapy for individuals, teens, and couples, as well as psychiatric treatment and medication management (18+). With Talkspace’s core therapy offerings, members are matched with one of thousands of licensed therapists within days and can engage in live video, audio, or chat sessions, and/or unlimited asynchronous text messaging sessions.

All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. More than 179 million Americans have access to Talkspace through their health insurance plans, employee assistance programs, our partnerships with leading healthcare companies, or as a free benefit through their employer, school, or government agency.

For more information, visitwww.talkspace.com.

Contacts

For Investors:
ICR Healthcare
[email protected]

For Media:
[email protected]



Western Union Media Network Taps Magnite to Expand Advertising Capabilities

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, today announced an agreement with Western Union to support growth of the financial services company’s new Media Network business. In doing so, Magnite will provide Western Union with technology to buy media as an advertiser and monetize its owned media.

To further increase direct access to streaming inventory, Western Union Media Network is the first commerce media company to leverage Magnite’s ClearLine solution. ClearLine puts clients in control of the ad buying process by allowing them to purchase premium streaming inventory directly from publishers, maximizing Western Union’s working media budget. Magnite reaches 92 million CTV households in the US, accounting for 9 out of 10 ad-supported CTV households in the country.

Magnite enables advertisers to tap into Western Union Media Network’s owned media properties and first-party insights. With Magnite’s technology, Western Union Media Network is monetizing its owned media properties spanning web, mobile, and in-app environments, including westernunion.com and its iOS and Android applications, which reach over 15 million US customers.

Using Magnite’s Curator Marketplaces for self-serve audience extension, Western Union Media Network is providing its customers access to a multicultural audience leveraging anonymized transaction data against Magnite inventory. As a result, advertisers and agencies can access Western Union’s unique data and Magnite’s premium inventory, benefiting from precise targeting and streamlined programmatic workflows.

Additionally, Western Union and Magnite have signed a supply-path optimization (SPO) agreement to streamline Western Union’s access to curated, premium omnichannel inventory.

“Magnite’s expansive technology and service offerings make them a versatile partner that can help address our desire to grow our business,” said Chris Hammer, Senior Vice President, Western Union. “We are excited to see this collaboration continue to grow as we scale our Media Network business.”

“We’re proud to support Western Union Media Network’s entry into advertising by helping them activate efficiently on all fronts,” said Stephanie Reustle, Head of Commerce Media at Magnite. “It’s great to see the advanced technology we’ve built for publishers and advertisers providing value to clients in new fields. We’ve seen the firsthand benefits of bringing sellers and buyers closer together and helping commerce media brands integrate into the landscape will bring additional advantages for all.”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

About Western Union

The Western Union Company (NYSE: WU) is committed to helping people around the world who aspire to build financial futures for themselves, their loved ones, and their communities. Our leading cross-border, cross-currency money movement, payments, and digital financial services empower consumers, businesses, financial institutions, and governments—across more than 200 countries and territories and over 130 currencies—to connect with billions of bank accounts, millions of digital wallets and cards, and a global footprint of hundreds of thousands of retail locations. Our goal is to offer accessible financial services that help people and communities prosper. For more information, visit www.westernunion.com.

Media Contact:

Kar Yi Lim
[email protected]

Investor Relations Contact:

Nick Kormeluk
[email protected]
949-500-0003



MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30

MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13752696

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:

Matt Notarianni
Investor Relations
470-304-7291
[email protected]



Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C.

Presentation Information:

Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination
Speaker: Dr. James F. Cummings
Date: Wednesday, April 23, 2025
Time: 1:10 p.m. ET
Room: 207A

Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection
Speaker: Dr. Sean Tucker
Date: Wednesday, April 23, 2024
Time: 3:10 p.m. ET
Room: 207A

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations:   
Matt Steinberg     
FINN Partners
[email protected]
(646) 871-8481

This press release was published by a CLEAR® Verified individual.



Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025

SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Media Contact

[email protected]

Investor Contact

[email protected]



Algorhythm Holdings Announces 2024 Financial Results

Fort Lauderdale, FL, April 16, 2025 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – an AI technology and consumer electronics holding company, announced today its results of operations for the twelve months period ended December 31, 2024.

2024 Financial Highlights*

  • The Company reported revenue of $23.5 million for the year ended December 31, 2024 compared to $29.2 million for the nine-month period ended December 31, 2023.
  • Gross profit was $4.8 million for the year ended December 31, 2024, compared to $6.2 million for the nine-month period ended December 31, 2023, with gross margins of 20.4% and 21.2% for the two periods, respectively.
  • Loss from operations increased $7.8 million to $13.9 million for the year ended December 31, 2024, compared to $6.1 million for the nine-month period ended December 31, 2023.
  • Net loss increased $18 million to $24.4 million for the year ended December 31, 2024, compared to $6.1 million for the nine-month period ended December 31, 2023.
  • Adjusted net loss, a non-GAAP measure, was $7.6 million for the year ended December 31, 2024, compared to $2.6 million for the nine-month period ended December 31, 2023.
  • Inventory was successfully reduced by 68%, from $6.9 million as of December 31, 2023 to $2.2 million as of December 31, 2024.
  • The Company bolstered its cash on hand to $7.6 million as of December 31, 2024.

A reconciliation of adjusted loss from operations and adjusted net loss on a GAAP and non-GAAP basis is included in the table below entitled “Reconciliation of GAAP to non-GAAP Financial Measures”.

*During 2023, the Company changed fiscal year end from March 31 to December 31. In accordance with SEC regulations, the Company’s consolidated financial statements consisted of balance sheets at December 31, 2024 and 2023 and its statements of operations, stockholders’ deficit and cash flows for the year ended December 31, 2024 and the nine-month period ended December 31, 2023. All numbers presented in this press release reflect these periods.

2024 Overview

“This past year marked a pivotal and exciting time for Algorhythm Holdings,” stated Gary Atkinson, Chief Executive Officer of the Company. “During the year, we began the process of transforming the company from a consumer electronics company offering karaoke products to an artificial intelligence (AI) company offering freight technology services to the transportation industry.”

“Let me briefly recap the several noteworthy achievements and organizational changes that we made during the past 12 months to support the long-term profitability of Algorhythm Holdings:

  • We entered the AI space by acquiring the United States business of SemiCab, Inc., an emerging artificial intelligence driven logistics company.
  • We completed a number of corporate actions designed to better position the company for future growth, including changing our name to Algorhythm Holdings.
  • We raised more than $10 million of capital to pay off substantially all of our liabilities and debt and provide us with the capital necessary to support the growth and development of our SemiCab business.
  • We hired Alex Andre to serve as our CFO and GC, who brings us 25 years of executive management, financial and legal experience in high-growth public and private companies with particular strength with M&A, capital raises and SEC matters.

Additionally, through service agreements, we have been investing in the growth and development of SemiCab, Inc.’s India business (SemiCab India). SemiCab India onboarded a number of notable pilot contracts onto SemiCab, Inc.’s AI logistics platform during the past year, including Apollo Tyres, a top ten global tire manufacturer based in India and two multinational consumer packaged goods manufacturers. These contracts, among others, have resulted in substantial growth in its week-over-week revenue. We plan to complete the acquisition of SemiCab India later this month.”

Financial Summary

“We generated $23.5 million of revenue this past year compared to $29.2 million for the nine-month comparative period in 2023,” commented Alex Andre, CFO and General Counsel of the Company. “The decrease was primarily due to decreases in sales of our karaoke products to one of our retailers that resulted from us not participating in its national Black Friday promotion and a loss of retail shelf space at another retailer. We expect sales of our karaoke products to decrease over the next 12 months due to the negative impact on our business of recently implemented tariffs on our products manufactured in China. However, we expect revenue generated from our SemiCab business to increase over the next 12 months as we generate more business from our customer base in the United States and integrate revenue generated by SemiCab India upon our acquisition of the company later this month.”

“Our net loss was $24.4 million this past year compared to $6.1 million for the nine-month comparative period in 2023. The increase was due primarily to a substantial increase in non-cash expenses that we incurred in connection with our acquisition of SemiCab’s US business in July 2024 and the capital raising activities that we engaged in during Q4 2024. Of our 2024 net loss, $16.7 million was for non-cash expenses. The most significant components of these non-cash expenses were a one-time charge of $3.6 million for goodwill impairment and a one-time, non-cash charge of $8.9 million for warrants that we issued in December 2024 as part of a capital raise. As a result, after deducting all of the non-cash expenses, our adjusted net loss was $7.6 million for 2024.”

The impairment of goodwill charge was associated with the Company’s acquisition of SemiCab, Inc.’s US business. The partial write-off of goodwill was expected as the Company’s SemiCab business is a nascent, emerging business that the Company purchased for its technology, management team and customer contracts, but that had negligible revenue at the time it was acquired. The warrants that the Company issued in December 2024 were subject to certain contingencies that resulted in the Company having to record a warrant liability of $16.6 million on its balance sheet and a loss of $8.9 million on its income statement. All of the contingencies that the warrants were subject to were satisfied or became moot in January 2025. As a result, the Company expects the entire warrant liability to reverse out(?) and be reclassified to equity on its balance sheet for its fiscal quarter ended March 31, 2025.

Outlook

“We are very excited for what 2025 has in store for us, notwithstanding the precarious economic environment that world is maneuvering through,” added Mr. Atkinson. “The foundation of our strategy moving forward will be the continued growth and development of SemiCab, our AI-enabled freight tech logistics and distribution business. The opportunity in this segment of the AI space is very large, and SemiCab, with its cutting-edge technology, is receiving a lot of interest from multinational, Fortune 500 customers as a result. In furtherance of this strategy, we are also evaluating strategic alternatives for our Singing Machine business, including a potential sale of the business. The continued investment in our legacy karaoke and consumer electronics products no longer aligns with our shift to the AI logistics and distribution industry.”

“Our future is brighter than it has ever been. The decisions we’ve made have been bold and decisive to try to turn around the Company. We believe we are making the right investments in the people, assets and companies to allow us to grow quickly and efficiently during 2025. When I reflect upon how far we’ve come during the past year, I could not be more motivated and optimistic about what we will achieve in the future.”

Non-GAAP Financial Measures

The Company prepares it’s consolidated financial statements in accordance with United States generally accepted accounting principles (“GAAP”). In addition to disclosing financial information prepared in accordance with GAAP, this release also includes non-GAAP operating income, non-GAAP net income and non-GAAP net income per share data for the periods presented. Management uses non-GAAP financial measures internally for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company’s management believes that these non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the Company’s core business operations, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

These non-GAAP financial measures are not recognized measures for financial statement presentation under U.S. GAAP and do not have standardized meanings. Accordingly, they may be different from similar non-GAAP financial measures presented by other companies. These non-GAAP financial measures should only be used to evaluate the Company’s results of operations in conjunction with the corresponding GAAP financial measures. Investors should consider these non-GAAP financial measures as a supplement to, and not as a substitute for, corresponding financial measures calculated in accordance with GAAP.

For the purposes of this press release, the following non-GAAP financial measures have the following meanings:

Adjusted net loss” means net loss plus depreciation, amortization of intangible assets, impairment of goodwill from purchase of SemiCab, Inc., impairment on note receivable – SMCB, reduction in SMCB loan in exchange for services, provision for estimated cost of returns, change in fair value of warrant liability, loss on issuance of warrants, amortization of debt discount and issuance costs, provision for inventory obsolescence, reserve for sales returns, credit losses, non-cash effect on termination of operating lease, net gain from disposal of property and equipment, stock-based compensation and amortization of right of use assets.

For further information, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2025 and available online at www.sec.gov.

For a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please see the table below entitled “Reconciliation of GAAP to Non-GAAP Financial Measures”.

About Algorhythm Holdings

Algorhythm Holdings, Inc. is a holding company with two primary investments. First, the Company owns SemiCab Holdings, an emerging leader in the AI-enabled global logistics industry. Second, the Company owns The Singing Machine Company, the worldwide leader in the consumer karaoke industry.

SemiCab is a cloud-based Collaborative Transportation Platform built to achieve the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. To orchestrate collaboration across manufacturers, retailers, distributors, and their carriers, SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners. To build fully loaded round trips, SemiCab uses AI/ML predictions and advanced predictive optimization models. On the SemiCab platform, shippers pay less and carriers make more while not having to change a thing.

Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address these common supply-chain problems globally. SemiCab’s Orchestrated Collaboration AI model has proven to increase transportation capacity, improve asset utilization, reduce empty miles, lower logistics costs, and provide visibility into the entire transportation network. Models show the technology has the capability of saving shippers tens of billions of dollars annually through optimization. Further, SemiCab’s technology also has the potential to play a key role in the improved sustainability model globally. Based on its proven ability to improve truck utilization rates from 65% to over 90%, this results in a dramatic reduction in the carbon footprint of the industry. The optimization of existing truck utilization can add approximately 30% more trucking capacity without adding more trucks, drivers or driven miles which addresses common problems plaguing the industry like severe driver shortage and road congestion. Trucking optimization could also eliminate approximately 25% of CO2 emissions attributable to road freight.

For additional information about SemiCab: http://www.semicab.com

The Singing Machine Company, Inc. is the worldwide leader in consumer karaoke products. Based in Fort Lauderdale, Florida, and founded over forty years ago, the Company designs and distributes the industry’s widest assortment of at-home and in-car karaoke entertainment products. Their portfolio is marketed under both proprietary brands and popular licenses, including Carpool Karaoke and Sesame Street. Singing Machine products incorporate the latest technology and provide access to over 100,000 songs for streaming through its mobile app and select WiFi-capable products and is also developing the world’s first globally available, fully integrated in-car karaoke system. The Company also has a new philanthropic initiative, CARE-eoke by Singing Machine, to focus on the social impact of karaoke for children and adults of all ages who would benefit from singing. Their products are sold in over 25,000 locations worldwide, including Amazon, Costco, Sam’s Club, Target, and Walmart.

For additional information about Singing Machine: www.singingmachine.com.

Investor Relations Contact

[email protected]


www.algoholdings.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the Company’s Annual Report on Form 10- for the year ended December 31, 2024.

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.

Algorhythm Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

Table 1: Adjusted Net Loss

    For the Year Ended December 31, 2024     For the Nine Months Ended December 31, 2023  
             
Net loss (as reported)   $ (24,367,000 )   $ (6,398,000 )
                 
Depreciation     192,000       287,000  
Amortization of intangible assets     30,000        
Impairment of goodwill from purchase of SemiCab Inc     3,592,000        
Impairment on note receivable – SCMB     439,000        
Reduction in SMCB loan in exchange for services     637,000        
Provision for estimated cost of returns     299,000       (1,364,000 )
Change in fair value of warrant liability     (334,000 )      
Loss on issuance of warrants     8,889,000        
Amortization of debt discount and issuance costs     1,520,000        
Provision for inventory obsolescence     918,000       1,798,000  
Reserve for sales returns     (35,000 )     2,490,000  
Credit losses     14,000       8,000  
Non-cash effect on termination of operating lease     (280,000 )      
Net gain from disposal of property and equipment           (44,000 )
Stock based compensation     630,000       110,000  
Amortization of right of use assets     236,000       510,000  
                 
Adjusted net loss   $ (7,620,000 )   $ (2,603,000 )



Algorhythm Holdings, Inc. and Subsidiaries


Consolidated Balance Sheets (Unaudited)

    December 31, 2024     December 31, 2023  
             
Assets                
 Current Assets                
 Cash   $ 7,550,000     $ 6,703,000  
 Accounts receivable, net of allowances of $274,000 and $174,000, respectively     4,373,000       7,308,000  
 Accounts receivable, related party     212,000       269,000  
 Note receivable – related party     701,000        
 Inventory     2,186,000       6,871,000  
 Returns asset     1,621,000       1,919,000  
 Prepaid expenses and other current assets     120,000       136,000  
            Total Current Assets     16,763,000       23,206,000  
                 
 Property and equipment, net     284,000       404,000  
 Operating leases – right of use assets     95,000       3,926,000  
 Other non-current assets     29,000       179,000  
 Intangible assets, net     345,000        
 Goodwill     786,000        
           Total Assets   $ 18,302,000     $ 27,715,000  
                 

 Liabilities and Shareholders’ Equity
               
 Current Liabilities                
 Accounts payable   $ 3,808,000     $ 7,616,000  
 Accrued expenses     4,224,000       2,614,000  
 Refund due to customer     38,000       1,743,000  
 Customer prepayments           687,000  
 Reserve for sales returns     3,355,000       3,390,000  
 Warrant liability     16,603,000        
 Current portion of notes payable to related parties     265,000        
 Other current liabilities     145,000       159,000  
         Total Current Liabilities     28,438,000       16,209,000  
                 
 Notes payable to related parties, net of current portion     385,000        
 Operating lease liabilities, net of current portion           3,925,000  
 Other liabilities           3,000  
           Total Liabilities     28,823,000       20,137,000  
                 
 Commitments and Contingencies                
                 
 Shareholders’ (Deficit) Equity                
 Preferred stock, $1.00 par value; 1,000,000 shares authorized; no                
   shares issued and outstanding            
 Common stock $0.01 par value;  100,000,000 shares authorized;                
 470,825 and 32,090 shares issued and outstanding at December 31, 2024 and 2023.     5,000        
 Additional paid-in capital     39,682,000       33,493,000  
 Accumulated deficit     (49,172,000 )     (25,915,000 )
 Non-controlling interest     (1,036,000 )      
         Total Algorhythm Holdings Shareholders’ (Deficit) Equity     (10,521,000 )     7,578,000  
                 
         Total Liabilities and Shareholders’ (Deficit) Equity   $ 18,302,000     $ 27,715,000  



Algorhythm Holdings, Inc. and Subsidiaries


Consolidated Statements of Operations (Unaudited)

    Year Ended     Nine Months Ended  
    December 31, 2024     December 31, 2023  
             
Net Sales   $ 23,494,000     $ 29,198,000  
                 
Cost of Goods Sold     18,713,000       23,008,000  
                 
Gross Profit     4,781,000       6,190,000  
                 
Operating Expenses                
Selling expenses     2,874,000       3,717,000  
General and administrative expenses     12,240,000       8,616,000  
Impairment of goodwill     3,592,000        
Total Operating Expenses     18,706,000       12,333,000  
                 
Loss from Operations     (13,925,000 )     (6,143,000 )
                 
Other (Expense) Income                
Change in fair value of warrant liability     334,000        
Loss on issuance of warrants     (8,889,000 )      
Interest expense     (1,887,000 )     (299,000 )
Other income           44,000  
Total Other Expense     (10,442,000 )     (255,000 )
                 
Loss Before Income Tax Benefit     (24,367,000 )     (6,398,000 )
                 
Income Tax Provision            
                 
Net Loss     (24,367,000 )     (6,398,000 )
                 
Net Loss Attributable to Non-controlling Interest     1,110,000        
                 
Net  Loss Available to Common Stockholders   $ (23,257,000 )   $ (6,398,000 )
                 
Loss per common share                
Basic and diluted   $ (353.87 )   $ (263.04 )
                 
Weighted Average Common and Common                
Equivalent Shares:                
Basic and diluted     65,722       24,323  



Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types

Continued progress of lead program, AKTX-101, for the treatment of solid tumors

Platform technology to fuel pipeline with ability to generate novel

ADC candidates across a range of solid/hematological cancers

Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline

Cash on hand expected to be sufficient to fund planned operations into September 2025

BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today reported its financial results for the fiscal year ended December 31, 2024 and provided a corporate update.

“2024 was a transformational year for Akari with the successful completion of our merger with Peak Bio Inc., and renewed focus on advancing our next-generation precision ADC pipeline candidates,” commented Samir R. Patel, M.D., President and Chief Executive Officer of Akari Therapeutics. “Looking ahead, we have made strategic leadership appointments with key skillsets to continue setting the Company up for success. We recently announced the appointment of Abizer Gaslightwala, a seasoned oncology executive with an impressive track record, who will serve as Akari’s President and Chief Executive Officer, effective April 21, 2025. I believe with our innovative platform technology and preclinical data demonstrated to date, Akari is well-positioned to become a key player in the ADC space and capitalize on the significant deal-flow seen in early ADC development. We look forward to an exciting year ahead and remain focused on the successful execution of our capital-efficient development strategies.”

Program Highlights

Following the completed merger with Peak Bio, Inc. in November 2024, Akari has focused its efforts on the discovery, research and development of novel anti-cancer payloads with mechanisms of action that differ from currently approved ADC therapies and the application of those payloads against clinically validated targets. Leveraging its platform, the Company is advancing a pipeline of potentially first-in-class, best-in-class ADC candidates that are designed to target and kill cancer cells and stimulate the immune system, or bifunctional ADCs, all while potentially overcoming the limitations inherent in existing therapies.

Lead Candidate: AKTX-101 (TROP2 PH1 ADC) – Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

  • Potential to overcome shortcomings of current ADCs
    • Immunostimulatory effects
    • Reduced off-target toxicity
    • Overcomes resistance mechanisms
    • Potential for synergy with immunotherapies
  • Significant advantages over current TROP2 ADCs observed in multiple preclinical models:
    • Superior activity
    • Prolonged survival
    • Less resistance
    • Better tolerability
    • Prolonged survival in combination with checkpoint inhibitors (CPI)

Upcoming Expected Value-Driving Milestones

Next-Generation Precision Bi-Functional ADC Platform

  • Present anticipated PH1 Payload preclinical data at scientific conference
  • Complete additional preclinical studies for AKTX-101
  • Continue to advance pipeline by generating additional validating data on PH1 payload while advancing discovery work on additional novel payloads PH5 and PH6
  • Round out Executive Team with critical hires
  • Seek licensing/strategic partner for AKTX-101 (TROP2 PH1 ADC)

Legacy Pipeline Assets

  • Continue Business Development efforts to secure development partners and provide non-dilutive capital

Summary of Financial Results for Full Year 2024

The net loss from operations for the year ended December 31, 2024 was approximately $21.6 million compared to approximately $16.8 million for the comparable period in 2023. The increase in net loss from operations is primarily attributable to merger related costs of $3.3 million, restructuring costs of $1.7 million and an increase in research and development expenses of $1.5 million which was offset by a reduction in general and administrative expenses of $1.7 million.

The Company reported research and development expenses of $7.0 million for the year ended December 31, 2024 compared to approximately $5.5 million for the comparable period in 2023.

General and administrative expenses were approximately $9.7 million for the year ended December 31, 2024 compared to approximately $11.4 million for the year ended December 31, 2023.

As of December 31, 2024, the Company had cash of approximately $2.6 million. Management anticipates that its cash on hand as of December 31, 2024 including the net proceeds from the private placement of $6.6 million announced in March 2025, is sufficient to fund operations into September 2025.

About Akari Therapeutics

Akari Therapeutics is a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its innovative ADC discovery platform, the Company has the ability to generate novel bi-functional ADC candidates and optimize them based on the desired application to target a range of cancers to fuel a growing pipeline. Akari’s lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their toxin classes, PH1 is a novel bi-functional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Given this mechanism, AKTX-101 has the potential to overcome many of the shortcomings of current ADCs, off-target toxicity and resistance. In preclinical studies, AKTX-101 has shown to have superior activity, prolonged survival, less resistance and better tolerability and safety. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival in preclinical models. The Company is generating validating data on its novel payloads to advance its pipeline.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates; financial projections; future economic performance; business development efforts and securing business development partners and the assumptions underlying or relating to such statements. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]

AKARI THERAPEUTICS, PLC

Consolidated Balance Sheets

(amounts in thousands, except share and per share data)
 
    December 31,  
    2024     2023  
ASSETS            
Current assets:            
Cash   $ 2,599     $ 3,845  
Restricted cash     60        
Prepaid expenses     92       299  
Other current assets     201       197  
Total current assets     2,952       4,341  
Goodwill     8,430        
Other intangible assets     39,180        
Patent acquisition costs, net           14  
Total assets   $ 50,562     $ 4,355  
             
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)            
Current liabilities:            
Accounts payable   $ 12,407     $ 1,671  
Accrued expenses     3,137       1,566  
Convertible notes     700        
Convertible notes, related party     250        
Notes payable     659        
Notes payable, related party     1,651        
Warrant liabilities     1,012       1,253  
Other current liabilities     94       94  
Total current liabilities     19,910       4,584  
Other non-current liabilities     383        
Deferred tax liability     8,040        
Total liabilities     28,333       4,584  
             
Commitments and contingencies (Note 10)            
             
Shareholders’ equity (deficit):            
Share capital of $0.0001 par value            
Authorized: 245,035,791,523 and 45,122,321,523 ordinary shares at
December 31, 2024 and 2023, respectively; issued and outstanding:
53,186,919,523 and 13,234,315,298 at December 31, 2024 and 2023,
respectively
    5,319       1,324  
Additional paid-in capital     212,706       174,754  
Capital redemption reserve     52,194       52,194  
Accumulated other comprehensive loss     (738 )     (1,040 )
Accumulated deficit     (247,252 )     (227,461 )
Total shareholders’ equity (deficit)     22,229       (229 )
Total liabilities and shareholders’ equity (deficit)   $ 50,562     $ 4,355  

AKARI THERAPEUTICS, PLC

Consolidated Statements of Operations and Comprehensive Loss

(amounts in thousands, except share and per share data)
 
   
    Year Ended  
    December 31,  
    2024     2023  
Operating expenses:            
Research and development   $ 6,983     $ 5,450  
General and administrative     9,664       11,356  
Merger-related expenses     3,273        
Restructuring and other expenses     1,723        
Total operating expenses     21,643       16,806  
Loss from operations     (21,643 )     (16,806 )
Other income (expense):            
Interest income     8       82  
Interest expense     (244 )      
Change in fair value of warrant liabilities     2,085       6,599  
Foreign currency exchange gains (losses), net     6       136  
Other expense, net     (3 )     (19 )
Total other income, net     1,852       6,798  
Net loss   $ (19,791 )   $ (10,008 )
             
Net loss per share –– basic and diluted   $ (0.00 )   $ (0.00 )
Weighted-average number of ordinary shares used in computing net loss per share –– basic and diluted     23,888,010,485       9,788,980,193  
             
Comprehensive loss:            
Net loss   $ (19,791 )   $ (10,008 )
Other comprehensive income, net of tax:            
Foreign currency translation adjustment     302       (269 )
Total other comprehensive income, net of tax     302       (269 )
Total comprehensive loss   $ (19,489 )   $ (10,277 )



The Vita Coco Company to Report First Quarter 2025 Financial Results on April 30, 2025

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the “Company”), a leading high-growth platform of better-for-you beverage brands, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, April 30, 2025 before market open. The Company will host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day.

To participate in the live earnings call and question and answer session, please register here and dial-in information will be provided directly to you. The live audio webcast will be accessible in the “Events” section of the Company’s Investor Relations website at https://investors.thevitacococompany.com/. An archived replay of the webcast will be available shortly after the live event has concluded.

ABOUT THE VITA COCO COMPANY

The Vita Coco Company is a family of brands on a mission to reimagine what’s possible when brands deliver healthy, nutritious, and great tasting products that are better for consumers and better for the world. This includes its flagship coconut water brand Vita Coco, sustainably packaged water Ever & Ever, and protein-infused water PWR LIFT. The Company was co-founded in 2004 by Michael Kirban and Ira Liran and is a public benefit corporation and Certified B Corporation. Vita Coco, the principal brand within the Company’s portfolio, is the leading coconut water brand in the U.S. With electrolytes, nutrients, and vitamins, coconut water has become a top beverage choice among consumers after a workout, in smoothies, as a cocktail mixer, after a night out, and more.

CONTACTS

Investor:
ICR, Inc.
[email protected]

Media:
[email protected]



Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study

RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.

FORGETDIABETES is funded by the European Union’s Horizon 2020 research and innovation program, a multi-year funding program with €75 Billion to support initiatives ranging from basic research to innovative product development. The groundbreaking FORGETDIABETES initiative is dedicated to developing a bionic invisible pancreas, which will free people with type 1 diabetes from therapeutic actions and the related psychological burden. Glucotrack’s Continuous Blood Glucose Monitor (CBGM) will provide real-time glucose readings to drive insulin delivery decisions for the bionic pancreas system.

“We are committed to the goal of revolutionizing treatment for people with type 1 diabetes, forever changing the medical approach towards this disease burden,” said Claudio Cobelli, PhD, Emeritus Professor of Bioengineering at the University of Padova in Padova, Italy, who serves as Coordinator for the initiative. “The longevity, accuracy and convenience of Glucotrack’s CBGM make it more automatic and less intrusive to daily living than other glucose monitoring methods and thus an ideal complement for our bionic pancreas technology.”

Despite significant advancements in diabetes technology, such as subcutaneous continuous glucose sensors and insulin pumps, daily management remains a substantial burden for many people living with diabetes. The FORGETDIABETES initiative aims to alleviate this burden by developing a groundbreaking bionic pancreas technology. This innovative solution seeks to transform diabetes from a disease that requires constant attention into a more manageable lifestyle condition, much like wearing long-term contact lenses. By simplifying diabetes management, the bionic pancreas has the potential to revolutionize the lives of countless individuals, allowing them to focus on their daily activities without the constant worry and interruptions associated with traditional diabetes care.

“We are thrilled to be part of the groundbreaking FORGETDIABETES initiative, which aligns perfectly with our mission to transform diabetes management through innovative and accessible technology,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “At Glucotrack, we are committed to redefining what life with diabetes can look like by providing simplified, discreet monitoring with our CBGM. Integration into automated insulin delivery systems is a key priority for us. We are honored to join FORGETDIABETES to develop a fully implantable closed loop system for people living with diabetes.”

Participants in the FORGETDIABETES initiative include the Department of Women & Child’s Health at University of Padova, Padova (Italy), the BioRobotics Institute at Sant’Anna School of Advanced Studies, Pisa (Italy), Pfützner Science & Health Institute GmbH, Mannheim (Germany), Centre Hospitalier Universitaire de Montpellier (France), Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (Germany) and WaveComm, SME, Siena (Italy).

The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

About Glucotrack, Inc.

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.

Contacts:

Investor Relations:
[email protected]

Media:
[email protected]